

HETEROCYCLIC COMPOUND ACTING ON G12D MUTANT KRAS PROTEIN

ABSTRACT

To provide a compound useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer.

The present inventors have studied about a compound that is useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer and have found that heterocyclic compounds represented by the formula (I) have an excellent degradation-inducing action on a G12D mutant KRAS protein and/or a G12D mutant KRAS inhibition activity and can be used as a therapeutic agent for pancreatic cancer, thus completing the present invention. The heterocyclic compound or a salt thereof of the present invention can be used as a therapeutic agent for pancreatic cancer.